Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

ImmunoPrecise Antibodies Ltd. (IPA) had Revenue of $17.59M for the most recently reported fiscal year, ending 2025-04-30.

Quarterly Annual

Figures for fiscal year ending 2025-04-30

Income Statement Financials
Revenue	$17.59M
Net Income	$-21.69M
Cost of Goods Sold	$7.87M
Gross Profit	$9.72M
Operating Expenses	$26.47M
Operating Income	$-8.88M
Non-Operating Income/Expense	$-15.71M
Pre-Tax Income	$-24.59M
Normalized Pre-Tax Income	$-9.39M
Income after Taxes	$-21.69M
Income from Continuous Operations	$-21.69M
Consolidated Net Income/Loss	$-21.69M
Normalized Income after Taxes	$-4.70M
EBIT	$-8.88M
EBITDA	$-5.21M
Weighted-Average Shares Outstanding (Basic)	33.38M
Weighted-Average Shares Outstanding (Diluted)	33.38M
Earnings per Share (EPS) (Basic)	$-0.65
Earnings per Share (EPS) (Diluted)	$-0.65
Balance Sheet Financials
Current Assets	$13.46M
Property, Plant, and Equipment	$11.31M
Long-Term Assets	$18.43M
Total Assets	$31.89M
Current Liabilities	$6.47M
Long-Term Debt	$8.29M
Long-Term Liabilities	$8.47M
Total Liabilities	$14.93M
Common Equity	$16.95M
Tangible Shareholders Equity	$10.28M
Shareholders Equity	$16.95M
Common Shares Outstanding	46.15M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-4.60M
Cash Flow from Investing Activities	$-0.57M
Cash Flow from Financial Activities	$10.69M
Beginning Cash	$2.54M
End Cash	$7.74M
Increase/Decrease in Cash	$5.20M
Stock-Based Compensation	$0.32M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.08
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.33
Debt to Equity Ratio	0.57
Gross Margin	55.25%
Operating Margin	-50.47%
EBIT Margin	-50.47%
EBITDA Margin	-29.60%
Pre-Tax Profit Margin	-139.75%
Profit Margin	-123.30%
Free Cash Flow	$-5.17M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.55
Inventory Turnover	5.24
Receiveable Turnover	5.76
Days Sales in Receivables	63.38
Return on Equity	-127.97%
Return on Tangible Equity	-211.00%
Return on Assets	-68.03%
Return on Investments	-85.94%
Book Value Per Share	$0.37
Free Cash Flow per Share	$-0.15
Operating Cash Flow per Share	$-0.14

Data from Zacks Investment Research, Inc.